ACRO Announces Grant Recipients for Diverse Clinical Research
Recently, ACRO revealed the seven clinical research sites selected to receive funding through its Diversity and Inclusion Site Resource Grants Program. This initiative aims to foster innovative strategies essential for improving diverse enrollment in clinical studies.
Supported Research Sites
The seven grant awardees span across various locations, demonstrating a commitment to enhancing diversity within clinical trials:
Brooklyn Clinical Research
K2 Medical Research
Nebraska Cancer Specialists
Preferred Primary Care Physicians
Randomize Now
Smart Cures Clinical Research
Superior Clinical Research
Each of these sites will engage in a 12-month program, entirely dedicated to experimenting with methods that better encourage diverse participation within clinical research.
Goals of the Grants Program
ACRO is optimistic that the Diversity and Inclusion Site Resource Grants Program will illuminate these projects as models of success. Tafoya Hubbard, the Grants Program Manager at ACRO, emphasized the importance of this undertaking by stating, 'We hope that ACRO’s D&I Site Resource Grants Program will help to elevate these seven projects as proof-of-concept initiatives to show the broader industry that a small investment can go a long way toward improving representation in clinical trials.'
Inclusivity in Clinical Trials
The Diversity & Inclusion in Clinical Trials Committee of ACRO evaluated proposals from a wide array of sites. They included community-based locations needing support and established firms enhancing the diversity of trial participants.
Over the upcoming year, ACRO will collaborate closely with the selected sites to monitor their growth and offer necessary assistance. The Program will conclude with a comprehensive white paper detailing the learned experiences and findings from this endeavor.
The Role of ACRO
Doug Peddicord, Executive Director of ACRO, articulated the organization's commitment: 'The clinical research and clinical technology companies of ACRO are key connectors of sponsors, sites, and trial participants. We are extremely excited to inaugurate this project, which aims to experiment with various approaches to improving the diversity of clinical trial populations, and we anticipate enlightening results and insights.' This project not only showcases ACRO's dedication to diversity but also its role in bridging gaps between participants and research sponsors.
About ACRO
Established in 2002, ACRO represents some of the leading clinical research and technology organizations around the globe. They offer specialized services vital to the advancement of drugs, biologics, and medical devices. ACRO and its members strive worldwide for safe, ethical, and high-quality medical research, ensuring patients benefit from new therapies and treatments. With a focus on efficiency and innovation, ACRO is dedicated to enhancing the clinical research process.
Frequently Asked Questions
What is the ACRO Diversity and Inclusion Site Resource Grants Program?
This program provides grant funding to clinical research sites aimed at improving diverse enrollment in clinical trials.
How many sites received funding?
Seven clinical research sites were awarded funding through this program.
Who manages the Grants Program at ACRO?
Tafoya Hubbard is the Grants Program Manager overseeing this initiative.
What will happen over the next 12 months?
ACRO will support the awarded sites and track their progress while collecting insights to be shared in a white paper.
What is ACRO's mission?
ACRO aims to promote safe and ethical clinical research practices to enhance the availability of new treatments and therapies for patients.
